GlassScriptPhysician profile
Roger D Mclain
NPI 1053524140
$799.03
in general payments reported to CMS, 2019-2025
14 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $279 · 2023: $180 · 2024: $83.25 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $314.23 | 2022-2024 | Proclaim |
| Medtronic, INC. | $105.52 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Collegium Pharmaceutical, INC. | $94.42 | 2021-2025 | Xtampza |
| Almatica Pharma LLC | $49.24 | 2021-2022 | |
| Abbvie INC. | $47.43 | 2023-2025 | |
| Averitas Pharma INC. | $38.69 | 2023-2024 | Qutenza |
| Redhill Biopharma INC. | $34.95 | 2021 | |
| Saluda Medical Americas, INC. | $26.16 | 2023 | Evoke Scs |
| Scilex Pharmaceuticals INC. | $18.28 | 2021 | |
| Boston Scientific Corporation | $16.91 | 2025 | Spectra Wavewriter |
| Protega Pharmaceutials INC | $14.40 | 2023 | Roxybond |
| Pacira Pharmaceuticals Incorporated | $14.02 | 2023 | Zilretta, Iovera, Exparel |
| Biodelivery Sciences International, INC. | $13.30 | 2021 | |
| Ibsa Pharma INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Mclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.